X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
This financing provides the enhanced financial flexibility to develop the gene and cell therapies, including CD123 CAR-T, in fully integrated cell processing facility in Worcester, Mass. that has capacity to launch at commercial scale.
Lead Product(s): Relmapirazin
Therapeutic Area: Oncology Product Name: CD123 CAR-T
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Runway Growth Capital
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing March 08, 2022
Details:
The Phase 1 portion of the trial will determine the maximum tolerated dose of MB-102 for the Phase 2 portion of the trial. Safety will be assessed at each dose level before proceeding to the next.
Lead Product(s): Relmapirazin,Decitabine,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: MB-102
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 01, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
